jetcityimage/iStock Editorial via Getty Images
- Despite a previous decision declining a potential marketing authorization application, Eli Lilly (NYSE:LLY) received backing from an expert panel of the EU drug regulator, the European Medicines Agency (EMA), for its Alzheimer’s treatment donanemab on Friday.
- The Indiana-based drugmaker said that